
## Marina Romero-Ramos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7645942/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microglia Acquire Distinct Activation Profiles Depending on the Degree of α-Synuclein Neuropathology in a rAAV Based Model of Parkinson's Disease. PLoS ONE, 2010, 5, e8784.	1.1	207
2	Neuroimmunological Processes in Parkinson's Disease and their Relation to α-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity. ASN Neuro, 2013, 5, AN20120066.	1.5	197
3	Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain, 2007, 130, 799-815.	3.7	186
4	GDNF fails to exert neuroprotection in a rat Â-synuclein model of Parkinson's disease. Brain, 2011, 134, 2302-2311.	3.7	157
5	Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention. Frontiers in Cellular Neuroscience, 2018, 12, 247.	1.8	152
6	The relation between α-synuclein and microglia in Parkinson's disease: Recent developments. Neuroscience, 2015, 302, 47-58.	1.1	141
7	Distribution of Na/Kâ€ATPase alpha 3 isoform, a sodiumâ€potassium Pâ€ŧype pump associated with rapidâ€onset of dystonia parkinsonism (RDP) in the adult mouse brain. Journal of Comparative Neurology, 2011, 519, 376-404.	0.9	139
8	Periphery and brain, innate and adaptive immunity in Parkinson's disease. Acta Neuropathologica, 2021, 141, 527-545.	3.9	133
9	Neuronal differentiation of stem cells isolated from adult muscle. Journal of Neuroscience Research, 2002, 69, 894-907.	1.3	129
10	Immune system responses in Parkinson's disease: Early and dynamic. European Journal of Neuroscience, 2019, 49, 364-383.	1.2	104
11	Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model. Journal of Neuroscience, 2016, 36, 9375-9390.	1.7	99
12	α-Synuclein expression is modulated at the translational level by iron. NeuroReport, 2012, 23, 576-580.	0.6	93
13	Coâ€expression of Câ€terminal truncated alphaâ€synuclein enhances fullâ€length alphaâ€synucleinâ€induced pathology. European Journal of Neuroscience, 2010, 32, 409-422.	1.2	90
14	Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiology of Disease, 2006, 23, 522-532.	2.1	89
15	α-Synuclein Vaccination Prevents the Accumulation of Parkinson Disease-Like Pathologic Inclusions in Striatum in Association With Regulatory T Cell Recruitment in a Rat Model. Journal of Neuropathology and Experimental Neurology, 2013, 72, 624-645.	0.9	86
16	Suppression of Map Kinases Inhibits Microglial Activation and Attenuates Neuronal Cell Death Induced by α-Synuclein Protofibrils. International Journal of Immunopathology and Pharmacology, 2009, 22, 897-909.	1.0	76
17	Adult Reserve Stem Cells and Their Potential for Tissue Engineering. Cell Biochemistry and Biophysics, 2004, 40, 1-80.	0.9	67
18	Alterations in Blood Monocyte Functions in Parkinson's Disease. Movement Disorders, 2019, 34,	2.2	67

<sup>.8 1711-1721.</sup> 

MARINA ROMERO-RAMOS

#	Article	IF	CITATIONS
19	Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates. Neuroscience, 2012, 208, 85-96.	1.1	61
20	Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease. Scientific Reports, 2017, 7, 6363.	1.6	58
21	Multiple system atrophy-associated oligodendroglial protein p25î± stimulates formation of novel α-synuclein strain with enhanced neurodegenerative potential. Acta Neuropathologica, 2021, 142, 87-115.	3.9	55
22	Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. Experimental Neurology, 2013, 247, 45-58.	2.0	53
23	Progressive striatonigral degenerationÂin a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. Acta Neuropathologica Communications, 2018, 6, 2.	2.4	50
24	Isolation and characterization of cells with neurogenic potential from adult skeletal muscle. Biochemical and Biophysical Research Communications, 2004, 317, 893-901.	1.0	44
25	Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiology of Disease, 2013, 56, 47-58.	2.1	42
26	PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. Neurobiology of Disease, 2021, 149, 105229.	2.1	36
27	Vaccination strategies for Parkinson disease. Human Vaccines and Immunotherapeutics, 2014, 10, 852-867.	1.4	35
28	α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology. Journal of Neuroinflammation, 2016, 13, 74.	3.1	35
29	Soluble <scp>CD163</scp> Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. Movement Disorders, 2021, 36, 963-976.	2.2	35
30	Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	35
31	Viral Vector Mediated Overexpression of Human α-Synuclein in the Nigrostriatal Dopaminergic Neurons: A New Model for Parkinson's Disease. CNS Spectrums, 2005, 10, 235-244.	0.7	31
32	Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration. Neurobiology of Disease, 2017, 106, 279-290.	2.1	28
33	Size-Selective Phagocytic Clearance of Fibrillar α-Synuclein through Conformational Activation of Complement Receptor 4. Journal of Immunology, 2020, 204, 1345-1361.	0.4	23
34	In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 819-830.	2.4	22
35	Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson's disease and cognition. Brain, Behavior, and Immunity, 2022, 101, 182-193.	2.0	20
36	Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system. Brain Research, 1995, 672, 153-158.	1.1	19

#	Article	IF	CITATIONS
37	CD4 T cells react to local increase of α-synuclein in a pathology-associated variant-dependent manner and modify brain microglia in absence of brain pathology. Heliyon, 2018, 4, e00513.	1.4	18
38	Low selenium diet induces tyrosine hydroxylase enzyme in nigrostriatal system of the rat. Molecular Brain Research, 2000, 84, 7-16.	2.5	16
39	Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies. Journal of Parkinson's Disease, 2022, 12, S149-S163.	1.5	15
40	Immunolocalization of human alpha-synuclein in the Thy1-aSyn ("Line 61â€) transgenic mouse line. Neuroscience, 2014, 277, 647-664.	1.1	12
41	Chronic Inhibition of the High-Affinity Dopamine Uptake System Increases Oxidative Damage to Proteins in the Aged Rat Substantia Nigra. Free Radical Biology and Medicine, 1997, 23, 1-7.	1.3	11
42	Less induced 1-methyl-4-phenylpyridinium ion neurotoxicity on striatal slices from guinea-pigs fed with a vitamin C-deficient diet. Neuroscience, 1997, 77, 167-174.	1.1	9
43	Transplantation of multipotent cells extracted from adult skeletal muscles into the subventricular zone of adult rats. Journal of Comparative Neurology, 2005, 491, 96-108.	0.9	7
44	Decreased messenger RNA expression of key markers of the nigrostriatal dopaminergic system following vitamin E deficiency in the rat. Neuroscience, 2000, 101, 1029-1036.	1.1	6
45	Semichronic Inhibition of Glutathione Reductase Promotes Oxidative Damage to Proteins and Induces both Transcription and Translation of Tyrosine Hydroxylase in the Nigrostriatal System. Free Radical Research, 2003, 37, 1003-1012.	1.5	6
46	α-Synuclein Overexpression Increases Dopamine D2/3 Receptor Binding and Immune Activation in a Model of Early Parkinson's Disease. Biomedicines, 2021, 9, 1876.	1.4	5
47	Increased Activity and Expression of Tyrosine Hydroxylase in the Rat Substantia Nigra after Chronic Treatment with Nomifensine. Molecular Pharmacology, 1997, 52, 641-647.	1.0	4
48	Alpha Synuclein in Parkinson's Disease. , 2014, , 691-726.		4
49	Immune response during idiopathic Parkinson's disease: From humans to animal models. International Review of Movement Disorders, 2021, 2, 261-301.	0.1	1
50	Changes in the Immune System in Parkinson's Disease. , 2018, , 1-21.		0
51	Changes in the Immune System in Parkinson's Disease. , 2019, , 2353-2373.		0